Loading
Tricision is a Beijing company working on mRNA medicines and cancer vaccines. Its lead cancer product is a vaccine made from a patient's own immune cells loaded with survivin, a protein found in glioblastoma, given after diagnosis.
Beijing Tricision Biotherapeutics (Qichensheng) was founded in 2015, according to the company, and develops mRNA nucleic acid medicines, with mRNA, nanoparticle and cell delivery platforms and wholly owned subsidiaries in Zhuhai, Guangdong, and Yixing, Jiangsu; its pipeline covers mRNA cancer therapies and mRNA vaccines for infectious disease. Its lead cancer programme is a survivin-targeted dendritic cell injection for glioblastoma, and the company announced the start of a phase 2 trial. Its first registered cancer trial, NCT06524063, a phase 1 study of survivin-loaded dendritic cell injection in newly diagnosed glioblastoma, was posted on ClinicalTrials.gov in July 2024; a phase 2 study (NCT07715097) followed in July 2026.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/